You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
悦康藥業(688658.SH):子公司獲得核酸藥物遞送系統發明專利
格隆匯 04-22 17:43

格隆匯4月22日丨悦康藥業(688658.SH)公佈,公司子公司北京悦康科創醫藥科技股份有限公司於近日收到國家知識產權局頒發的發明專利證書。專利名稱:一種陽離子脂質化合物、包含其的組合物及用途。

“一種陽離子脂質化合物、包含其的組合物及用途的專利”是核酸藥物遞送系統的重要專利,主要保護的是具有全新化學結構的一系列可電離陽離子脂質,以及以其為主體制備的LNP組合物。遞送系統是核酸藥物成藥的關鍵技術,脂質納米顆粒(Lipid Nanoparticle,LNP)可高效的遞送核酸藥物,LNP由陽離子脂質、膽固醇、輔助脂質、PEG修飾的脂質4個部分組成,其中最核心的成分是陽離子脂質。公司獲得授權的發明專利中的可電離陽離子脂質具有全新化學結構,組合物具有生物可降解、安全性好、遞送效率高、可提高核酸藥物穩定性的優勢,將極大的提升核酸藥物的遞送水平。

LNP遞送系統是目前唯一經過大規模臨牀驗證的mRNA藥物遞送系統,具有極高的技術壁壘。“一種陽離子脂質化合物、包含其的組合物及用途的專利”的獲批,對公司核酸藥物平台具有重要的里程碑的意義,受專利保護的可電離陽離子脂質將成為公司核酸藥物遞送系統的基石,以其為主體制備的LNP組合物可以實現對核酸藥物的高效遞送。該專利獲得授權標誌着公司擁有了獨立自主知識產權的可電離陽離子脂質、包含其的組合物及用途,可極大的增強公司核酸藥物研發能力,擴充核酸藥物管線。

上述發明專利的取得是公司核酸平台建設的重要成果,是公司重要核心技術的體現和延伸,有利於進一步完善公司知識產權保護體系,發揮自主知識產權的技術優勢,有利於公司進一步加強核酸平台建設,邁入國際創新前沿,促進技術創新,形成持續創新機制,從而提升公司的創新能力、核心競爭力以及綜合實力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account